Priscilla Chan on Broadening Rare-Disease Research

A short argument for putting research tools in more hands, with context on spinal muscular atrophy.

PCPriscilla ChanPonente
Canal
No Priors: AI, Machine Learning, Tech, & Startups
Publicado
7 jul 2026
Vídeo
1:03
Lectura
1 min
Original
inglés
Abrir en YouTube
Al desplazarte, el vídeo se reduce a la esquina inferior derecha y sigue reproduciéndose. Los subtítulos siguen tu idioma de lectura.
Idioma de lecturaDisponible en 2 idiomas
Este artículo aún no está en español, así que se muestra el original en inglés.
RESUMEN

En 30 segundos

Priscilla Chan argues that rare diseases may be overlooked by research strategies focused on large populations. She suggests broader access to tools could support more targeted research; SMA already has active research and approved treatments.

  1. 1A long tailCommon disease categories contain many distinct subtypes, alongside rare diseases.
  2. 2Broader accessChan argues for giving more researchers tools to pursue neglected questions.
  3. 3SMA contextSMA has active research and approved treatments.

Conclusiones

  1. Disease categories include many subtypes.
  2. Rare diseases can receive less attention in population-focused research.
  3. Chan favors broader access to research tools.
  4. SMA already has approved treatments.
TEXTO COMPLETO

Lee el texto editado por capítulos

Solo la transcripción
01

Researching the long tail

Priscilla Chan argues that disease categories contain many subtypes, and that rare conditions may receive less attention when research focuses on interventions affecting the largest numbers of people.

Priscilla Chan argues that disease categories contain many subtypes, and that rare conditions may receive less attention when research focuses on interventions affecting the largest numbers of people.

She proposes putting research tools in more people’s hands so that individuals and smaller groups can pursue conditions they care about. As an example, she mentions spinal muscular atrophy (SMA).

Chan suggests that studying a rare disease can also reveal broader biological mechanisms. This is an argument for widening research participation, not a guarantee that a particular tool or project will produce a treatment.

SMA is already the subject of active research and has approved treatments; it should not be understood from the clip’s headline as a disease nobody studies. For example, the FDA has approved gene therapy for specified SMA patients. [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy).

Más de este canal

38:06EN
No Priors: AI, Machine Learning, Tech, & Startups· 29 oct 2026Pódcast · 3 vocesServal’s Jake Stauch on coding agents for enterprise ITInvitado: Jake Stauch · Presenta: Sarah Guo, Elad GilStauch explains why Serval is challenging ServiceNow, how it approaches permissions and approvals, and why background agents remain difficult to deploy safely.IA empresarialAgentes de programaciónWorkflow automation+2
39:23EN
No Priors: AI, Machine Learning, Tech, & Startups· 15 oct 2026Pódcast · 2 vocesThe Defenders' Window: Greg Brockman on AI-Generated Knowledge, Drug Discovery, and the New Physics of CybersecurityPresenta: Sarah Guo, Elad GilOpenAI's president explains why solving open math problems is a proof point for science, how proactive agents change product form, and why security spending must exceed software spending.SeguridadAI securitySeguridad y gobernanza+3
1:09:44EN
No Priors: AI, Machine Learning, Tech, & Startups· 9 oct 2026Pódcast · 2 voces10,000 GB300s for Four Weeks: Reflection’s Open-Model LedgerPresenta: Sarah Guo, Elad GilMisha Laskin tells No Priors how Reflection trained Beam, why reinforcement learning outspent pre-training, and why the West needs its own open weights.Código abierto y comunidadOpen-weight modelsReinforcement Learning+3
35:39EN
No Priors: AI, Machine Learning, Tech, & Startups· 2 oct 2026Pódcast · 2 vocesCompute Scaled a Millionfold. Bandwidth Only 40x. Fractile Wants to Fix That RatioPresenta: Sarah Guo, Elad GilIn the summer of 2022, Walter Goodwin founded Fractile in London to build very fast inference chips for the world's largest models.Infraestructura y despliegueInferenceAI cost & performance+3
42:44EN
No Priors: AI, Machine Learning, Tech, & Startups· 24 sept 2026Pódcast · 2 vocesThey Paid $7.7 Billion for a Broker — and Intend to Do One Deal a YearPresenta: Sarah Guo, Elad GilSequence Holdings co-founder Michael Lee tells No Priors why owning a market leader, not selling it software, is how AI actually remakes an incumbent.Empresa y estrategiaIA empresarialAI Strategy+3
38:14EN
No Priors: AI, Machine Learning, Tech, & Startups· 18 sept 2026Pódcast · 2 vocesDiffusion Will Win Inference: Stefano Ermon Bets Parallel Tokens Beat Custom SiliconPresenta: Sarah Guo, Elad GilThe Stanford diffusion pioneer tells No Priors why a 50-person lab is training language models that generate many tokens at once — and why that maps to GPUs the way transformers once mapped to training.Modelos y entrenamientoInferenceAI cost & performance+3